Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2012-01-26

FDA Approved: LUNESTA — Supplemental Application (Waylis Therapeutics LLC)

View source ↗

Summary

The FDA approved a supplemental application for LUNESTA (eszopiclone) from Waylis Therapeutics LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lunesta (eszopiclone)

Snippet

SUPPL AP for LUNESTA (ESZOPICLONE)